Wednesday 17 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Optibiotix - more details on cholesterol study - so far amazing

By HotStockRockets | Saturday 9 April 2016

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

A bloke in the City said that although results from Optibiotix's (OPTI) trials of its capsular supplement to reduce cholesterol looked great he was so fat that he was beyond redemption. Maybe. But for others results were startling. There is a caveat:

The twelve week double blind placebo controlled study recruited fifty volunteers and was designed to establish safety, compliance, and the extent of the cholesterol lowering potential of OptiBiotix's Lactobacillus plantarum strain in mildly hypercholesterolaemic adults.

50 is not a large study, bigger studies are needed. But the results on the small study were awesome. In Optibiotix's own words:

When volunteers taking placebo were compared to those taking OptiBiotix's capsular supplement the results showed a:-
· 7.2% reduction in LDL cholesterol (bad cholesterol) averaged across the whole test group
· 12.4% reduction in LDL cholesterol in females volunteers
· 15% reduction in the 50-55 age groups (both sexes)
· 36.7% reduction in volunteers' who had total cholesterol levels higher than 6mmol/L
· A 6mmHg (5.1%) reduction in systolic blood pressure averaged across the OptiBiotix group 
No safety, compliance, or tolerance issues were reported by volunteers during the study in either group.

Remember this is not a pharmaceutical and thus it is cheap and it appears to work. To quote the company :

These results suggest efficacy across all volunteers similar or greater to 1.5 - 2.4 g plant sterols/stanols per day, and in volunteers with total cholesterol level greater than 6mmol/L an efficacy more typically associated with pharmaceuticals.

Back to us:  This looks like it could have massive commercial potential with early deals with food companies very much on the cards. The shares are now 78-80p and at 80p or below are a strong buy ahead of results which are imminent

To catch the next share tip from HotStockRockets out shortly for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI



  1. Agreed the trial results are supportive, even if on a very small test sample.
    I’m curious whether your imminent news post Easter was the positive but nonetheless damp squib JV as opposed to a confirmed commercial tie up.

  2. The trial was way to small to draw much from . If a large independently run trial can replicate this then they are home and dry . Personally I think I will wait until they can start to monitise the concept in a meaningful way before entering again . It does however show great promise ……….I am just averse to losing my previous gains here .

  3. Simple Moving Avarice

    Yet another Lactobacillus plantarum strain. I’m sure it will fit right in with the rest of them.

  4. J P Spaghetti

    I’ve not been following developments here – sorry – but the fact the exercise was designed to identify any therapeutic effect as well as merely test safety implies this was a phase 2 trial. If so, its size was about a third of that typical at this stage. So small – yes – but still potentially meaningful. In fact, the saliva glands should be waking up (not just because of greed but altruism, of course!) if there was indeed a “7.2% reduction in LDL cholesterol (bad cholesterol) averaged across the whole test group” and it is a representative average. Based on the above alone, we don’t really know.

    The claim that there was a “36.7% reduction in volunteers’ who had total cholesterol levels higher than 6mmol/L” should have investors drooling, providing OPTI are not being slippery here (as would be the case, for instance, if only one or two participants had such high levels initially).

    There’s also the issue of commercialising non-proprietary substances (at least, active ingredients), but developments do indeed seem very exciting at this stage.

Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.

Site by Everywhen